771-99-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Phenylpiperidine is used as a key intermediate for the synthesis of various opioids, which are essential in the development of medications for pain management and treatment of opioid addiction. Its presence in the molecular structure of these drugs contributes to their analgesic and therapeutic properties.
Used in Organic Synthesis:
4-Phenylpiperidine is used as a versatile building block in organic synthesis, allowing for the creation of a wide range of chemical compounds with diverse applications.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Phenylpiperidine is utilized as a starting material for the development of new pesticides and other agricultural chemicals, contributing to enhanced crop protection and yield.
Used in Dyestuff Industry:
4-Phenylpiperidine is employed as a crucial component in the production of various dyes and pigments, providing color and functionality to a range of products in the dyestuff industry.

InChI:InChI=1/C11H15N/c1-2-4-10(5-3-1)11-6-8-12-9-7-11/h1-5,11-12H,6-9H2/p+1

Upstream product

• 939-23-1 p-phenylpyridine 
• 10338-69-9 1,2,3,6-tetrahydro-4-phenylpyridine 
• 81976-73-0 4-fenil-piperidin-2-one 
• 14149-31-6 4-phenylpiperidine-2,6-dione 
• 62143-51-5 1-(phenylmethyl)-4-phenylpiperidin-2,6-dione 
• 873380-11-1 3-phenyl-glutaric acid bis-benzylamide 
• 113237-07-3 4-Phenyl-piperidine-1-carboxylic acid 2-trimethylsilanyl-ethyl ester 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 
• 64-17-5 ethanol 
• 123-91-1 1,4-dioxane 
• 829-27-6 3-phenylpentane-1,5-diol 
• 110-58-7 n-Pentylamine 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 71-43-2 benzene 

Downstream Products

• 16376-62-8 3-(4-phenyl-piperidin-1-ylmethyl)-3H-benzooxazol-2-one 
• 34588-04-0 3-(4-phenyl-piperidin-1-ylmethyl)-3H-benzooxazole-2-thione 
• 56953-33-4 N-(β-idrossietil)-4-fenilpiperidina 
• 112611-57-1 (+/-)-trans-2-(4-phenylpiperidino)cyclopentanol 
• 134905-78-5 3-(4-bromophenyl)-2-hydroxy-1-[1-(4-phenylpiperidinyl)]propane 

Relevant academic research and scientific papers

Method for preparing piperidine compound by reducing pyridine compound through hydrogen transfer

The invention discloses a method for preparing a piperazine compound through a hydrogen transfer reduction of a pyridine compound, belonging to the field of organic synthesis. Under mild conditions, pyridine derivatives are used as raw materials, oxazolidine is used as a hydrogen transfer reagent, and cheap transition metals such as copper, cobalt, silver, palladium and the like are used as catalysts for catalysis of a hydrogen transfer reaction on 1,2,3,4-substitution sites, so a series of hydrogen transfer reduction product piperidine compounds are prepared, wherein the oxazaborolidine is obtained by a reaction of amino acid with a tetrahydrofuran complex of borane. The method has the advantages that product yield is high, reaction conditions are mild, the general applicability of raw materials is good, a hydrogen transfer reagent is cheap and easy to obtain, and good reproducibility can still be shown after quantitative reaction is conudcted. Therefore, the method of the invention provides an effective scheme for the industrial production of other high-value compounds containing the structure in the future.

Synthetic method of 4 -phenyl piperidine hydrochloride

The invention discloses a synthesis method of 4 -phenylpiperidine hydrochloride, and the route is as shown in the specification. The method has the advantages of cheap and easily available raw materials, simple operation and post-treatment, high yield, high product purity and the like, and is suitable for industrial production.

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Cobalt-bridged secondary building units in a titanium metal-organic framework catalyze cascade reduction of N-heteroarenes

We report here a novel Ti3-BPDC metal-organic framework (MOF) constructed from biphenyl-4,4′-dicarboxylate (BPDC) linkers and Ti3(OH)2 secondary building units (SBUs) with permanent porosity and large 1D channels. Ti-OH groups from neighboring SBUs point toward each other with an O-O distance of 2 ?, and upon deprotonation, act as the first bidentate SBU-based ligands to support CoII-hydride species for effective cascade reduction of N-heteroarenes (such as pyridines and quinolines) via sequential dearomative hydroboration and hydrogenation, affording piperidine and 1,2,3,4-tetrahydroquinoline derivatives with excellent activity (turnover number ～ 1980) and chemoselectivity.

Modulators of protease activated receptors

The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.

Direct Palladium-Catalyzed β-Arylation of Lactams

A direct and catalytic method is reported here for β-arylation of N-protected lactams with simple aryl iodides. The transformation is enabled by merging soft enolization of lactams, palladium-catalyzed desaturation, Ar?X bond activation, and aryl conjugate addition. The reaction is operated under mild reaction conditions, is scalable, and is chemoselective. Application of this method to concise syntheses of pharmaceutically relevant compounds is demonstrated.

Hydrogenation of Pyridines Using a Nitrogen-Modified Titania-Supported Cobalt Catalyst

Novel heterogeneous catalysts were prepared by impregnation of titania with a solution of cobalt acetate/melamine and subsequent pyrolysis. The resulting materials show an unusual nitrogen-modified titanium structure through partial implementation of nitrogen into the support. The optimal catalyst displayed good activity and selectivity for challenging pyridine hydrogenation under acid free conditions in water as solvent.

2,2,6,6-Tetramethylpiperidin-1-yloxycarbonyl: A Protecting Group for Primary, Secondary, and Heterocyclic Amines

The 2,2,6,6-tetramethylpiperidin-1-yloxycarbonyl (Tempoc) protecting group is readily introduced by the reaction of amines with a new acyl transfer reagent, 4-nitrophenyl (2,2,6,6-tetramethylpiperidin-1-yl) carbonate (NPTC). Tempoc has a reactivity profile that complements the commonly used t-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz) protecting groups. Deprotection can be achieved under mild reductive conditions with in situ generated Cu(I) species or by thermolytic cleavage at 135 °C. Mechanistic studies on the deprotection of Tempoc-indole suggest a combination of ionic and radical fragmentation pathways under thermal conditions.

Fluorine-containing sulfonyl compound as well as intermediate, preparation method and application thereof

The invention discloses a fluorine-containing sulfonyl compound as well as an intermediate, a preparation method and application thereof. The fluorine-containing sulfonyl compound disclosed by the invention comprises positive ions and negative ions, wherein the positive ions are shown as the formula I. The fluorine-containing sulfonyl compound can react with substrates to effectively synthetize the fluorine-containing sulfonyl compound; the toxicity is low; the preparation is simple; the use is convenient; the fluorine-containing sulfonyl compound is in a solid stable state at normal temperature. In addition, the substrate applicability of the compound is extremely wide, and a phenol compound and an amine compound can be included; the fluorine-containing sulfonyl compound is a unique solidformation reagent capable of realizing the chemical conversion at present, so that important academic and application values are realized. The formula I is shown in the description.

2-(Phenylseleno)ethanesulfon-amide as a novel protecting group for aniline that can be deprotected by a radical reaction

Anilines were protected as 2-(phenylseleno)ethanesulfonanilide (SeES anilide) via sulfonylation by 2-chlorosulfonyl chloride followed by the conjugate addition of benzeneselenol. The SeES anilide was deprotected by radical reduction using tributyltin hydride in the presence of AIBN. The corresponding anilines were obtained in high yields when the hydride and AIBN were added to the system slowly. Since the radical reaction proceeds under neutral conditions, chemoselective deprotection of the SeES group was accomplished. The SeES anilide was stable under various conditions, including some severe conditions.